Summary:
- The UK government has expanded its strategic partnership with CSL Seqirus to enhance national health security and pandemic preparedness.
- The agreement introduces a world-first adjuvanted cell-based influenza vaccine (aTIVc), which utilizes advanced manufacturing technology to provide broader protection compared to traditional egg-based vaccines.
- The deal secures long-term access to specialized vaccine manufacturing infrastructure, ensuring the UK can rapidly respond to emerging influenza threats and potential future pandemics.